Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM8G6O4)

Drug Name
AHPN Drug Info
Synonyms Ro 47-2077; 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid; CD437; CD 437
Cross-matching ID
PubChem CID
135411
ChEBI ID
CHEMBL1180
CAS Number
CAS 125316-60-1
TTD Drug ID
D0A6NQ

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
NF-kappa B signaling pathway 2.37 0.00e+0 90/104 (86.54%) CXCL8;PTGS2;GADD45A;...
Viral protein interaction with cytokine and cytokine re... 2.33 0.00e+0 84/100 (84%) CCL2;CXCL8;TNFRSF10B;...
IL-17 signaling pathway 2.29 0.00e+0 84/94 (89.36%) CCL2;CXCL8;FOSL1;...
TNF signaling pathway 2.29 0.00e+0 103/112 (91.96%) CCL2;JUN;PTGS2;...
p53 signaling pathway 2.28 0.00e+0 63/73 (86.3%) SESN1;CDKN1A;DDB2;...
Malaria 2.28 0.00e+0 44/50 (88%) CCL2;CXCL8;THBS2;...
Cytokine-cytokine receptor interaction 2.16 0.00e+0 246/295 (83.39%) CCL2;CXCL8;TNFRSF10B;...
Graft-versus-host disease 2.14 0.00e+0 32/42 (76.19%) FAS;IL6;IL1B;...
Small cell lung cancer 2.10 0.00e+0 90/92 (97.83%) CDKN1A;DDB2;PTGS2;...
Staphylococcus aureus infection 2.10 0.00e+0 72/95 (75.79%) KRT17;KRT18;KRT14;...
Epstein-Barr virus infection 2.07 0.00e+0 189/202 (93.56%) CDKN1A;JUN;DDB2;...
Arachidonic acid metabolism 1.98 0.00e+0 48/61 (78.69%) PTGS2;GPX2;ALOX5;...
Allograft rejection 1.95 0.00e+0 32/38 (84.21%) FAS;HLA-B;HLA-DQA1;...
Influenza A 1.95 0.00e+0 156/172 (90.7%) CCL2;CXCL8;NFKBIA;...
Chronic myeloid leukemia 1.95 0.00e+0 72/76 (94.74%) CDKN1A;DDB2;GADD45A;...
Herpes simplex virus 1 infection 1.92 6.48e-4 165/498 (33.13%) CCL2;NFKBIA;FAS;...
C-type lectin receptor signaling pathway 1.92 6.10e-4 93/104 (89.42%) JUN;PTGS2;NFKBIA;...
Rheumatoid arthritis 1.91 1.15e-3 78/93 (83.87%) CCL2;CXCL8;JUN;...
Type I diabetes mellitus 1.90 1.09e-3 38/43 (88.37%) FAS;IL1B;HLA-B;...
Cytosolic DNA-sensing pathway 1.90 1.04e-3 52/63 (82.54%) NFKBIA;IL6;CCL4;...
Kaposi sarcoma-associated herpesvirus infection 1.89 9.87e-4 172/193 (89.12%) CXCL8;CDKN1A;JUN;...
NOD-like receptor signaling pathway 1.89 1.41e-3 145/181 (80.11%) CCL2;CXCL8;JUN;...
Apoptosis 1.88 1.80e-3 126/168 (75%) JUN;GADD45A;NFKBIA;...
Legionellosis 1.88 1.73e-3 51/57 (89.47%) CXCL8;NFKBIA;CXCL2;...
Transcriptional misregulation in cancer 1.85 3.32e-3 158/192 (82.29%) CXCL8;CDKN1A;DDB2;...
Toll-like receptor signaling pathway 1.82 5.68e-3 94/104 (90.38%) CXCL8;JUN;NFKBIA;...
Leishmaniasis 1.82 5.51e-3 67/77 (87.01%) JUN;PTGS2;NFKBIA;...
Measles 1.81 5.34e-3 133/139 (95.68%) JUN;NFKBIA;TNFAIP3;...
Epithelial cell signaling in Helicobacter pylori infect... 1.81 5.18e-3 62/70 (88.57%) CXCL8;JUN;NFKBIA;...
Thyroid cancer 1.81 5.03e-3 36/37 (97.3%) CDKN1A;DDB2;GADD45A;...
Long-term depression -1.64 4.29e-2 55/60 (91.67%) MAP2K1;PLCB3;GUCY1B1;...
Cholinergic synapse -1.64 4.37e-2 99/113 (87.61%) MAP2K1;PLCB3;ITPR2;...
Gap junction -1.64 4.46e-2 72/88 (81.82%) MAP2K1;PLCB3;HTR2C;...
Carbohydrate digestion and absorption -1.66 3.54e-2 37/47 (78.72%) AKT2;HK1;PLCB3;...
Gastric acid secretion -1.67 3.58e-2 63/76 (82.89%) ADCY3;GNAI2;GNAS;...
Thyroid hormone signaling pathway -1.67 3.84e-2 112/121 (92.56%) MAP2K1;PLCB3;SLC16A10;...
Glutamatergic synapse -1.67 3.91e-2 97/114 (85.09%) GLS;GNB2;GRIA3;...
Sphingolipid signaling pathway -1.68 3.76e-2 106/119 (89.08%) GNA12;AKT3;KNG1;...
Adherens junction -1.69 3.58e-2 63/71 (88.73%) CTNNA2;PTPRF;SMAD4;...
Endocrine and other factor-regulated calcium reabsorpti... -1.71 2.88e-2 49/53 (92.45%) CLTA;GNAS;PLCB4;...
Long-term potentiation -1.75 2.03e-2 61/67 (91.04%) GRIA2;RAP1A;MAP2K2;...
Cell cycle -1.78 1.80e-2 110/124 (88.71%) SMC3;BUB3;RB1;...
Melanogenesis -1.81 1.51e-2 74/101 (73.27%) CALML5;DVL2;DVL3;...
Bacterial invasion of epithelial cells -1.86 1.28e-2 59/77 (76.62%) CTNNA2;DOCK1;RAC1;...
Regulation of actin cytoskeleton -1.91 5.76e-3 185/218 (84.86%) APC;ABI2;DIAPH3;...
Platelet activation -1.96 2.40e-3 106/124 (85.48%) P2RY1;RAP1B;TBXA2R;...
GnRH secretion -2.01 0.00e+0 60/64 (93.75%) MAP2K2;AKT2;ESR2;...
Oocyte meiosis -2.20 0.00e+0 90/129 (69.77%) PPP1CC;PPP2R5D;PGR;...
Progesterone-mediated oocyte maturation -2.22 0.00e+0 75/100 (75%) RPS6KA3;PIK3CA;MAPK3;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-673 CVCL_0080 Homo sapiens 12uM 6H
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.002uM - 12uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CL-34 CVCL_1123 Homo sapiens 12uM 6H
HT-29 CVCL_0320 Homo sapiens 12uM 6H, 24H
LoVo CVCL_0399 Homo sapiens 12uM 6H
MDST8 CVCL_1400 Homo sapiens 12uM 6H
NCI-H508 CVCL_1561 Homo sapiens 12uM 6H
SNU-1040 CVCL_5001 Homo sapiens 12uM 6H
SNU-C4 CVCL_5008 Homo sapiens 12uM 6H
SNU-C5 CVCL_5009 Homo sapiens 12uM 6H
SW480 CVCL_0546 Homo sapiens 12uM 6H
SW620 CVCL_0547 Homo sapiens 12uM 6H
SW948 CVCL_0550 Homo sapiens 12uM 6H
Colorectal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 CVCL_0291 Homo sapiens 12uM 6H
HT115 CVCL_1294 Homo sapiens 12uM 6H
RKO CVCL_0504 Homo sapiens 12uM 6H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 12uM 6H
SNG-M CVCL_1707 Homo sapiens 12uM 6H
Endometrial carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHUEM-2 CVCL_1327 Homo sapiens 12uM 6H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 12uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 12uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.002uM - 12uM 6H, 24H
DV-90 CVCL_1184 Homo sapiens 12uM 6H
SK-LU-1 CVCL_0624 Homo sapiens 12uM 6H
Lung adenosquamous carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H596 CVCL_1571 Homo sapiens 12uM 6H
Lung large cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COR-L23 CVCL_1133 Homo sapiens 12uM 6H
T3M-10 CVCL_1729 Homo sapiens 12uM 6H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC15 CVCL_1253 Homo sapiens 12uM 6H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1299 CVCL_0060 Homo sapiens 12uM 6H
HCC515 CVCL_5134 Homo sapiens 12uM 6H, 24H
NCI-H2073 CVCL_1523 Homo sapiens 12uM 6H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1694 CVCL_1495 Homo sapiens 12uM 6H
NCI-H1836 CVCL_1502 Homo sapiens 12uM 6H
Lymph node
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WSU-DLCL2 CVCL_1787 Homo sapiens 12uM 6H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
EFO-27 CVCL_1194 Homo sapiens 12uM 6H
OV7 CVCL_1623 Homo sapiens 12uM 6H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RMG-I CVCL_1663 Homo sapiens 12uM 6H
Ovarian mucinous cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV644 CVCL_2011 Homo sapiens 12uM 6H
RMUG-S CVCL_1666 Homo sapiens 12uM 6H
Ovarian undifferentiated carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TYK-nu CVCL_1774 Homo sapiens 12uM 6H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 12uM 6H
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NOMO-1 CVCL_1609 Homo sapiens 12uM 6H
PL-21 CVCL_2161 Homo sapiens 12uM 6H
SKM-1 CVCL_0010 Homo sapiens 12uM 6H
Pleural effusion
Histiocytic lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-937 CVCL_0007 Homo sapiens 12uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 12uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 12uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 12uM 6H, 24H
SK-MEL-1 CVCL_0523 Homo sapiens 12uM 6H
SK-MEL-28 CVCL_0526 Homo sapiens 12uM 6H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 12uM 6H